Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05795062 · ClinicalTrials.gov registry record
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 13,945
- Enrollment target
NCT05795062: Completed study, sponsored by Pfizer.
NCT05795062 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 13,945 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05795062 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 13,945 participants
- Enrollment target
Study Summary
The purpose of this study is to assess outpatient treatment patterns following hospitalization for venous thromboembolism (VTE). VTE is a condition that occurs when blood clot forms in the vein. This is a retrospective study (assessments on events that have already occurred) of healthcare claims from databases. The study sponsors will assess healthcare claim records of patients treated with either apixaban or warfarin. Assessment includes treatment persistence, switch, and stopping therapy, along with recurrent VTE and bleeding.
Primary Outcome
Following discharge from inpatient hospitalization, participants who continued apixaban or warfarin, respectively, in the outpatient setting (with outpatient treatment claim occurring on or within 30-days following the hospital discharge date) were identified.
Interventions
- DRUG warfarin
- DRUG apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,945 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2023-09-30 |
What the finished NCT05795062 record still lists
NCT05795062 is an observational study that tracks outcomes without assigning an intervention. Its 13,945 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which warfarin is the first listed.
NCT05795062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05795062 about?
NCT05795062 is a clinical study titled "Treatment Patterns Among Patients With Venous Thromboembolism in the United States". The purpose of this study is to assess outpatient treatment patterns following hospitalization for venous thromboembolism (VTE). VTE is a condition that occurs when blood clot forms in the vein. This is a retrospective study (assessments on events that have already occurred) of healthcare claims fr...
What is the current status of trial NCT05795062?
This trial is currently completed. The enrollment target is 13,945 participants. The study started on 2023-03-10. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT05795062?
The interventions under investigation include: warfarin (DRUG), apixaban (DRUG).
Who is sponsoring clinical trial NCT05795062?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI